Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Jul 27, 2014; 6(7): 520-526
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520
Table 4 Percentage of patients with normalization of alanine aminotransferase levels during different study periods n (%)
| Weeks | Genotype 1 | Genotype 31 | Genotype 4 |
| (n = 27) | (n = 56) | (n = 17) | |
| 4 | 16 (59.2) | 27 (48.2) | 8 (47.0) |
| 12 | 17 (62.9) | 29 (51.7) | 8 (47.0) |
| 24 | 17 (62.9) | 35 (62.5) | 9 (52.9) |
| 48 | 17 (62.9) | 40 (71.4) | 11 (64.7) |
| 72 | 17 (62.9) | - | 12 (70.6) |
- Citation: Rao P, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526
- URL: https://www.wjgnet.com/1948-5182/full/v6/i7/520.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i7.520